Graduated in Pharmacy and Biochemistry at the University of São Paulo (USP), master's and doctorate in Clinical Analysis (Microbiology) at the Faculty of Pharmaceutical Sciences - USP (FCF-USP). Post-doctorate in Clinical Analysis at FCF - USP, Department of Clinical Analysis, São Paulo, Brazil; Post-doctorate in Cell Biology at the National Center for Investigaciones Oncologicas, Department of Oncology, Madrid, Spain; Post-doctorate in Microbiology at the Institute of Biomedical Sciences - USP (ICB-USP), Department of Microbiology, São Paulo, Brazil; Young Researcher FAPESP (2016 to 2020) at the Department of Microbiology at ICB-USP. I am currently a researcher at the Vaccine Development Laboratory of the Butantan Institute and a collaborator of the Vaccine Development Laboratory of ICB-USP. Performance in the academic area: Coordinator in two Postgraduate Programs at USP: Interunit in Biotechnology (PPIB) and Microbiology at ICB; Professor Coordinator of University Extension Course disciplines at the Butantan Institute; Full Professor Advisor in two Postgraduate Programs: PPIB - USP and Microbiology at ICB-USP, Advisor at the Butantan Institute School (ESIB). Scientific area of #8203;#8203;activity: Basic Microbiology, Clinical Microbiology, Immunology, Ummuno-Oncology, Cell Biology, and Pathogenicity of Microorganisms, both with emphasis on the Pathogen-Host Cell interaction, as well as in immunotherapies for tumors. Experience in the development of vaccines and combined therapies for the treatment of tumors. ORCID ID: https://orcid.org/0000-0002-3024-8045. Researcher ID: H-4290-2012. Google Scholar - https://scholar.google.com/citations?hl=enuser=arSc5-MAAAAJview_op=list_works. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
In the last twelve years, solid evidence showed that the enzyme Indoleamine 2,3 dioxygenase-1 (IDO) is an important mediator of immune tolerance. While the similarities between IDO regulatory mechanisms and the molecular signature associated with cervical cancer and other tumors induced by human papillomavirus (HPV), the active role of IDO in these tumors has not been studied. Here, we wi…
Bladder cancer is one of the top ten most common cancers in the world, accounting for 90% of all urothelial malignancies. Approximately 70% of bladder tumors are non-muscle invasive at diagnosis and are treated with transurethral resection followed by intravesical Bacillus Calmette-Guérin instillation (BCG). This bacterium is used in cancer adjuvant therapy to reduce recurrence and metast…
Human Papillomavirus (HPV) is the etiologic agent of a variety of diseases, such as benign epithelial lesions, genital warts, laryngeal papillomas, and other diseases that are difficult to manage. In recent years, the role of HPV in triggering different types of tumors has been highlighted. It is known that HPV is responsible for more than 99% of cervical tumors, most of the anal tumors a…
Faithful to its inherent aggressive, melanomas are remarkably resistant to all forms of cancer therapies. The combination of chemotherapy with biomolecules such as IL-2 and IFN-alpha does not appear to be an effective management. However, clinical trials are underway to evaluate new therapeutic strategies. In this context, melatonin (MLT) has been shown to be an excellent adjunct to conve…
| 1 / 1 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 2 / 1 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 6 / 5 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID